PARP inhibitors suppress antitumor immunity by upregulating PD-L1 expression, whereas PD-L1 blockade restores T cell-mediated cytotoxicity against PARPi-treated cancer cells, thereby overcoming therapy-induced immune evasion [23]. This evidence concerns the gene PARP1 and cancer.